PhaseBio Pharmaceuticals (PHAS) IPO Opens Flat

Today's IPO for PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) opened for trading at $5 after pricing 9,200,000 shares of common stock at a price to the public of $5.

In addition, PhaseBio has granted the underwriters a 30-day option to purchase up to 1,380,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.

Citigroup, Cowen and Stifel acted as joint book-running managers for the offering. Needham & Company, LLC acted as co-manager for the offering.

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary, t

You May Also Be Interested In

• Chanos says SpaceX is not worth $1.75 trillion
• Leverage Shares by Themes Launches 2X Long and 2X Short SpaceX ETFs Following Historic SpaceX IPO
• Parabilis Medicines (PBLS) Opens at $33.35, IPO priced at $20, Trading $28.31